Sugi Predict

Sugi Predict / Compounds / SCHEMBL20790761

SCHEMBL20790761

SCHEMBL20790761

O=C(NCc1ccc(C(F)(F)F)cc1)C1CCCN1

nearest known ligand 0.72

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ HTR2C P28335 6/20 0.72
▸ HTR2B P41595 3/20 0.65
▸ KDM4E B2RXH2 1/20 0.55
▸ HDAC1 Q13547 5/20 0.52
▸ GID4 Q8IVV7 1/20 0.50
▸ P2RX7 Q99572 1/20 0.50
▸ HTR2A P28223 1/20 0.49
▸ KCNH2 Q12809 1/20 0.49
▸ HDAC3 O15379 3/20 0.48
▸ HDAC2 Q92769 2/20 0.48
▸ MC4R P32245 1/20 0.48
▸ HDAC10 Q969S8 1/20 0.48
▸ HDAC11 Q96DB2 1/20 0.48
▸ HDAC8 Q9BY41 1/20 0.48
▸ HDAC6 Q9UBN7 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6861205 1.00 HTR2C (0.72) HTR2CHTR2BKDM4EHDAC1GID4
SCHEMBL20790758 1.00 HTR2C (0.72) HTR2CHTR2BKDM4EHDAC1GID4
SCHEMBL20791266 0.96 HTR2C (0.67) HTR2CHTR2BKDM4EHDAC1GID4
SCHEMBL20791263 0.96 HTR2C (0.67) HTR2CHTR2BKDM4EHDAC1GID4
SCHEMBL20811644 0.95 HTR2C (0.66) HTR2CHTR2BKDM4EHDAC1GID4
SCHEMBL30524769 0.95 HTR2C (0.66) HTR2CHTR2BKDM4EHDAC1GID4
SCHEMBL20811294 0.93 HTR2C (0.62) HTR2CHTR2BKDM4EHDAC1P2RX7
SCHEMBL30524818 0.93 HTR2C (0.62) HTR2CHTR2BKDM4EHDAC1P2RX7
SCHEMBL30604551 0.90 HTR2C (0.77) HTR2CHTR2BKDM4EHDAC1HTR2A
Hydrochloric Acid SCHEMBL30002187 0.89 HTR2C (0.75) HTR2CHTR2BKDM4EHDAC1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240158372-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF AMGEN INC. 2024-05-16 — — US disclosed
CN-112745298-B Polysubstituted isoindoline compound, preparation method, pharmaceutical composition and application thereof 中国科学院上海药物研究所 2024-04-09 — — CN disclosed
US-11780826-B2 Bisamide sarcomere activating compounds and uses thereof AMGEN INC. (US) 2023-10-10 — — US disclosed
CN-111601798-B Bisamide sarcomere activating compounds and uses thereof 美国安进公司 2023-08-11 — — CN disclosed
US-20220281850-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF AMGEN INC. 2022-09-08 — — US disclosed
US-11299479-B1 Bisamide sarcomere activating compounds and uses thereof CYTOKINETICS, INC. (US) 2022-04-12 — — US disclosed
US-11254658-B2 Bisamide sarcomere activating compounds and uses thereof AMGEN INC. (US) 2022-02-22 — — US disclosed
US-10899746-B2 Bisamide sarcomere activating compounds and uses thereof AMGEN INC. (US) 2021-01-26 — — US disclosed
CN-111601798-A Bisamide sarcomere activating compound and use thereof 美国安进公司 2020-08-28 — — CN disclosed
US-10723720-B2 Bisamide sarcomere activating compounds and uses therof AMGEN INC. (US) 2020-07-28 — — US disclosed
EP-3681882-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF Amgen Inc. (US) 2020-07-22 — — EP disclosed
US-20200223829-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF AMGEN INC. 2020-07-16 — — US disclosed
US-20200223830-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF CYTOKINETICS, INC. 2020-07-16 — — US disclosed
WO-2019055590-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF AMGEN INC. (US) 2019-03-21 — — WO disclosed
US-20190077793-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF AMGEN INC. 2019-03-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11254658-B2 Bisamide sarcomere activating compounds and uses thereof TNNI3, TNNT2, TNNC1 HTR2C 4327/4885HTR2B 3581/4885KDM4E 898/4885
US-20200223830-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF TNNI3, TNNT2, TNNC1 HTR2C 4327/4885HTR2B 3581/4885KDM4E 898/4885
US-11780826-B2 Bisamide sarcomere activating compounds and uses thereof TNNI3, TNNT2, TNNC1 HTR2C 4327/4885HTR2B 3581/4885KDM4E 898/4885
US-20240158372-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF TNNI3, TNNT2, TNNC1 HTR2C 4327/4885HTR2B 3581/4885KDM4E 898/4885
US-20200223829-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF TNNI3, TNNT2, TNNC1 HTR2C 4327/4885HTR2B 3581/4885KDM4E 898/4885
US-20190077793-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF TNNI3, TNNT2, TNNC1 HTR2C 4327/4885HTR2B 3581/4885KDM4E 898/4885
US-10723720-B2 Bisamide sarcomere activating compounds and uses therof TNNI3, TNNT2, TNNC1 HTR2C 3674/4885HTR2B 2918/4885KDM4E 1820/4885
US-20220281850-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF TNNI3, TNNT2, TNNC1 HTR2C 4327/4885HTR2B 3581/4885KDM4E 898/4885
US-11299479-B1 Bisamide sarcomere activating compounds and uses thereof TNNI3, TNNT2, TNNC1 HTR2C 4327/4885HTR2B 3581/4885KDM4E 898/4885
US-10899746-B2 Bisamide sarcomere activating compounds and uses thereof TNNI3, TNNT2, TNNC1 HTR2C 4327/4885HTR2B 3581/4885KDM4E 898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.